patented technology to grow and expand adult Stem Cells

Adult stem cell development company commencing clinical trials applicable to estimated $30 billion degenerative disease market place

Free
Message: Emma - All of these stocks require Patience -

Don't count PTSC out yet. We are one re-exam away. EDIG has to go through what Patriot has already gone through - Lawsuits, Markman, Re-Exam etc.

I did pick up a very small amount of EDIG at .11 - which I could have bought more.

Pluristem requires the most patience - it is the longest shot IMO.

Share
New Message
Please login to post a reply